Emcure Pharmaceuticals Ltd's Q2 FY27 numbers came in strong, with revenue of Rs. 2,820.47 Cr (+24.26% YoY) and PAT growth of +29.32% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | November 03, 2026 |
|---|---|
| Revenue (Q2) | Rs. 2,820.47 Cr (+24.26% YoY) |
| PAT (Q2) | Rs. 325.07 Cr (+29.32% YoY) |
| EBITDA margin | 20.38% (+103 bps YoY) |
| EPS (Q2) | Rs. 17.16 (+33.50% YoY) |
Q2 FY27 revenue grew 24.26% YoY to Rs.2,820.47 Cr, running well ahead of the low-to-mid-teens FY27 guidance, with EBITDA margin up 103 bps YoY to 20.38% — at the top of the guided +70-100 bps band. International markets (59% of revenue) grew 34.5% YoY led by RoW (+41.1%) and EU (+36.0%), while the net debt build came in at less than half the guided amount. Material-cost ratio rose 131 bps YoY and gross margin fell 131 bps, but the mix bridge to EBITDA margin expansion held for another quarter.
| Driver | Expected before results | What happened | Verdict |
|---|---|---|---|
| Revenue "ahead to in-line vs the guided path" | FX tailwind + IPM tailwind | +24.26% YoY | Played out |
| Gross margin "pressure intact" vs ~59% guide (Q1 missed at 58.4%) | Headwind | 59.50% (Q2), back above guide — Q2 recovered | Partially |
| EBITDA margin "needs to stay inside +70–100 bps envelope" | Test of the bridge | +103 bps YoY | Played out |
| Net debt guided build Rs.450–500 Cr to ~Rs.1,450 Cr | "the single biggest reconciliation item" | Build Rs.214.10 Cr to Rs.1,317.10 Cr — build materially smaller than guided | Partially |
| Input costs "elevated, not spiking" pressure GM | Headwind | Material ratio +131 bps YoY — direction | Played out |
| Tax-demand and governance updates on the call | Watch items | Silent in the filing — carried forward for the call | Not observable |
Read our full results preview.
| What management said | Where | What happened | Verdict |
|---|---|---|---|
| FY27 revenue growth low-to-mid-teens, "higher end" | Q4 FY26 call; higher-end comfort reiterated on Q1 FY27 call | +24.26% YoY (Q2); +23.58% (H1) — running ahead | On Track |
| FY27 EBITDA margin expansion +70–100 bps | Q4 FY26 / Q1 FY27 calls | +103 bps YoY (Q2); +77 bps (H1) — Q2 within band | On Track |
| FY27 gross margin ~59% | Q1 FY27 call | 59.50% (Q2); 59.02% (H1) | Met in the quarter |
| Net debt ~Rs.1,450 Cr by end-Q2 | Q1 FY27 call (guided Rs.450–500 Cr build) | Rs.1,317.10 Cr — better than guided | Met |
| FY27 domestic growth low double-digit vs industry 8–9% | Q1 FY27 call | +12.03% YoY (Q2); +11.13% (H1) | On Track |
| FY27 R&D 4–5% of revenue | Q1 FY27 call | 3.93% (Rs.111.00 Cr) — low end | On Track |
| FY27 capex Rs.400–425 Cr | Q1 FY27 call | FY quantum not disclosed in filing; standalone H1 capex Rs.176.78 Cr | Too Early |
| Net cash by end-FY28 | Q1 FY27 call | Net debt Rs.1,317.10 Cr, up from Rs.1,053.80 Cr at Mar-26 | Too Early |
| "Q2 was another strong quarter… broad-based growth" (Satish Mehta) | Management commentary in the Q2 results press release | Revenue +24.26%, EBITDA +30.89%, all geographies double-digit | Confirmed |
| "EBITDA margin 20.4%, expansion of about 100 bps driven by productivity gains and operating leverage" | Same press release | +103 bps YoY on the company definition; employee/other costs grew below revenue | Confirmed |
| Metric | Q1 FY27 | Q2 FY27 |
|---|---|---|
| Product approvals (quarter) | 15+ | 20+ |
| R&D % of revenue | 3.5% | 3.93% |
| Net debt (Rs. Cr) | 1,103.0 | 1,317.10 |
| EBITDA margin % | 19.69 | 20.38 |
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.